Project Grant R43MH097383

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) program, provides $303,024 to Biocognon LLC to develop an innovative combinatorial nanobody discovery platform for G-protein coupled receptors (GPCRs). The key objectives of this 1-year project are to: 1) develop a robust assembly system for GPCR/nanobody libraries, 2) build a synthetic nanobody library targeting the ADRB1 and ADRB2 GPCRs and...

The National Institute of General Medical Sciences (NIGMS) awarded a $218,622 Project Grant to Vitan-Biotech LLC on September 22, 2023 under the Biomedical Research and Research Training program (CFDA 93.859). The grant will fund the development of an integrated pipeline to rapidly discover and characterize selective, high-affinity nanobodies against defined G protein-coupled receptors (GPCRs) that are important for neurological disorders like schizophrenia, pain, Parkinson's, Alzheimer's, and...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This $659,164 Project Grant awarded by the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), aims to identify pharmacological modulators, endogenous ligands, and binding partners for the orphan G protein-coupled receptor GPR156. The grant, awarded to the University of Rochester, will leverage innovative cell-based assays and proximity-mediated labeling technologies to discover new...

The University of North Carolina at Chapel Hill received a $466,500 Project Grant from the Department of Health and Human Services National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) to support research characterizing orphan G-protein coupled receptors (GPCRs) in lymphatic vessels. The award period is from May 1, 2021 through April 30, 2022. Specifically, the University will utilize in vitro and animal-based systems to further explore...

This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...